Evidence map›Paper›PMID 35401201›Full record

ReviewFrontiers in pharmacology2022

Potential Natural Small Molecular Compounds for the Treatment of Chronic Obstructive Pulmonary Disease: An Overview.

Liu-Ying Li, Chuan-Tao Zhang, Feng-Ya Zhu, Gang Zheng, Yu-Fei Liu, Ke Liu, Chen-Hui Zhang, Hong Zhang

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Protective Effect of the Total Alkaloid Extract from BulbusInternational journal of chronic obstructive pulmonary disease · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Liu-Ying LiDepartment of Heart Disease of Traditional Chinese Medicine, First People's Hospital of Zigong City, Zigong, China.
Chuan-Tao ZhangDepartment of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Feng-Ya ZhuDepartment of Heart Disease of Traditional Chinese Medicine, First People's Hospital of Zigong City, Zigong, China.
Gang ZhengDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Zigong City, Zigong, China.
Yu-Fei LiuDepartment of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Ke LiuDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Zigong City, Zigong, China.
Chen-Hui ZhangDepartment of Combine Traditional Chinese and Western Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Hong ZhangDepartment of Combine Traditional Chinese and Western Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Zigong First People's Hospital · CNChengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the major diseases threatening human life and health. According to the report released by the World Health Organization (WHO) in 2020, COPD has become the third leading cause of death in the world, featuring a sustainable growth of incidence rate as well as population age. The purpose of this review focuses on the advancement of bioactive natural compounds, such as baicalin, quercetin, resveratrol, and curcumin, which demonstrate promising therapeutic/interventional effects on CODP

Indexed as

alkaloidchronic obstructive pulmonary diseaseflavonoidsnatural compoundspolyphenol

Identifiers

PMID35401201
PMCPMC8988065
OpenAlexW4220661857

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.